乐普生物维贝柯妥塔单抗获批上市,成全球首个获批上市的EGFR-ADC;信达Q3营收33亿元,同比增长40%|制药在线一周药闻复盘

CPHI制药在线
Nov 01, 2025

点击蓝字关注我们本周,热点不少。首先是审评审批方面,很值得关注的就是,乐普生物维贝柯妥塔单抗获批上市,成为全球首个获批上市的EGFR-ADC;其次是研发方面,多个药取得重要进展,比如,信达生物玛仕度肽头对头司美格鲁肽Ⅲ期临床研究达到主要终点;再次是交易及投融资方面,荃信生物TSLP/IL-33双抗授权给罗氏,总交易额达10.7亿美元;上市方面,瑞博生物向港交所递交IPO申请;最后是财报方面,各大...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10